-
-
-
-
-
-
-
Piper Sandler Upgrades Capricor Therapeutics (CAPR) to Overweight 'Ahead of Extended 11/22 PDUFA Date'
-
-
-
-
-
-
-
Jones Trading Downgrades Capricor Therapeutics (CAPR) to Hold
-
-
-
-
-
-
-
Jones Trading on Capricor Therapeutics (CAPR): 'this is the first time we have seen the magnitude of difference in primary outcome'
-
-
-
-
-
-
-
B.Riley Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
-
-
-
-
-
-
Capricor reports positive HOPE-3 trial results for Duchenne therapy
-
-
-
-
-
-
-
CAPR receives FDA request for clinical study report on Deramiocel
-
-
-
-
-
-
-
B.Riley Starts Capricor Therapeutics (CAPR) at Buy
-
15,885 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


